Literature DB >> 9028732

Activation of TRK genes in Ewing's sarcoma. Trk A receptor expression linked to neural differentiation.

E Nogueira1, S Navarro, A Pellín, A Llombart-Bosch.   

Abstract

Trk receptors have been identified by immunohistochemical methods in primitive neuroectodermal tumor (PNET)/Ewing's sarcoma (ES). However, the presence of different members of the Trk family of receptors in PNET/ES has not been specified. We have examined whether Trk A, B, and C receptors are specifically expressed in ES both with and without features of neural differentiation. Ten ES tumors (five primary tumors of bone and five extraosseous tumors transplanted into nude mice) were investigated for expression of Trk receptors by immunohistochemistry and reverse transcription-polymerase chain reaction. One primary ES and the five grafted ES tumors exhibited signs of neural differentiation; the remaining four primaries were undifferentiated ES. Other tumor types were analyzed as controls; they included three neuroblastomas (NB), two lymphomas, and single cases of pheochromocytoma (PHEO), schwannoma (SCHW), osteosarcoma, and carcinoma of breast, colon, and kidney. Trk receptors were detected in paraffin-embedded tumor tissue sections by means of a pan-Trk polyclonal antibody raised against the 14 carboxy-terminal residues of gp140trk, and trk A, B, and C transcripts were specifically detected by polymerase chain reaction-based amplification on cDNAs derived from tumor RNA with MuLV reverse transcriptase. Reactivity to the pan-Trk antibody was exhibited by six ES tumors, the three NBs, and the single PHEO and SCHW cases; immunoreactivity was restricted to differentiated tumors, in the case of ES. Tumor types positive for immunostaining were also distinguished by containing transcripts of TRK genes. However, the trk A, B, and C expression pattern of ES differed from that of NBs, PHEO, and SCHW. Transcripts of trk A, B, and C were detected in seven, four, and one case of ES, respectively, and in five, two, and five cases of NB, PHEO, and SCHW, respectively. Interestingly, all differentiated ES tumors contained trk A transcripts. Tumors of neuroectodermal phenotype and/or derivation were thus characterized by a distinct consensus expression pattern: trk A+/B-/C+ for differentiated ES and trk A+/B-/C+ for NB-PHEO-SCHW. These results indicate that the TRK gene family is frequently activated in ES; they also suggest that Trk A receptor is a feature of ES with neural differentiation, whereas Trk B and C receptors seem to be present in undifferentiated ES.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9028732     DOI: 10.1097/00019606-199702000-00003

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  2 in total

1.  Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.

Authors:  Radhika Iyer; Lea Wehrmann; Rebecca L Golden; Koumudi Naraparaju; Jamie L Croucher; Suzanne P MacFarland; Peng Guan; Venkatadri Kolla; Ge Wei; Nicholas Cam; Gang Li; Zachary Hornby; Garrett M Brodeur
Journal:  Cancer Lett       Date:  2016-01-18       Impact factor: 8.679

2.  Trk inhibition reduces cell proliferation and potentiates the effects of chemotherapeutic agents in Ewing sarcoma.

Authors:  Tiago Elias Heinen; Rafael Pereira Dos Santos; Amanda da Rocha; Michel Pinheiro Dos Santos; Patrícia Luciana da Costa Lopez; Marco Aurélio Silva Filho; Bárbara Kunzler Souza; Luís Fernando da Rosa Rivero; Ricardo Gehrke Becker; Lauro José Gregianin; Algemir Lunardi Brunetto; André Tesainer Brunetto; Caroline Brunetto de Farias; Rafael Roesler
Journal:  Oncotarget       Date:  2016-06-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.